三阴性乳腺癌
乳腺癌
纳米载体
纳米医学
微泡
转移
癌症
雌激素受体
表皮生长因子受体
固体脂质纳米粒
医学
内科学
癌症研究
化学
纳米技术
药理学
材料科学
小RNA
药品
纳米颗粒
生物化学
基因
作者
Vikas Jain,Hitesh Kumar,Haritha V. Anod,Pallavi Chand,Neha Gupta,Sangeeta Dey,Siddharth S. Kesharwani
标识
DOI:10.1016/j.jconrel.2020.07.003
摘要
Breast cancer (BC) is one of the most prevalent cancers in women. Triple-negative breast cancer (TNBC) in which the three major receptors i.e. estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), are absent is known to express the most aggressive phenotype and increased metastasis which results in the development of resistance to chemotherapy. It offers various therapeutic advantages in treating BC and TNBC. Nanotechnology offers various unique characteristics such as small size (nanometric), active and passive targeting, and the ability to attach multiple targeting moieties, controlled release, and site-specific targeting. This review focuses on conventional drug therapies, recent treatment strategies, and unique therapeutic approaches available for BC and TNBC. The role of breast cancer stem cells in the recurrence of BC and TNBC has also been highlighted. Several chemotherapeutic agents delivered using nanocarriers such as polymeric nanoparticles/micelles, metallic/inorganic NPs, and lipid-based NPs (Liposome, solid-lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs)), etc. with excellent responses in the treatment of BC/TNBC along with breast cancer stem cells have been discussed in details. Moreover, the application of nanomedicine including CRISPR nanoparticle, exosomes for the treatment of BC/TNBC and other molecular targets available such as poly (ADP-ribose) polymerase (PARP), epidermal growth factor receptor (EGFR), Vascular endothelial growth factor (VEGF), etc. for further exploration have also been discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI